Chelation therapy in β-thalassemia: An optimistic update
Authors:
- Robert W GradyRGRobert W Grady
- 1 October 2001
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 38 (4) , 360-366
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- New trends in the treatment of β-thalassemiaCritical Reviews in Oncology/Hematology, 2000
- DeferiproneDrugs, 1999
- Pathophysiology of Iron OverloadaAnnals of the New York Academy of Sciences, 1998
- Thalassemia in the Next Millennium: Keynote AddressaAnnals of the New York Academy of Sciences, 1998
- Evaluation of a new method of administration of the iron chelating agent deferoxamineThe Journal of Pediatrics, 1997
- Results of Long-Term Iron-Chelating TherapyActa Haematologica, 1996
- Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron ChelatorsBritish Journal of Haematology, 1995
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Therapy for β-Thalassemia -- A Paradigm for the Treatment of Genetic DisordersNew England Journal of Medicine, 1994
- Oral Iron Chelators for the Clinical Management of Iron OverloadAnnals of the New York Academy of Sciences, 1990